Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O'demethylation of R- and S-naproxen

Biochemical Pharmacology

Volumn 51, Issue 8, 1996, Pages 1003-1008

  Miners, John O ^a   Coulter, Sally ^a   Tukey, Robert H ^b   Veronese, Maurice E ^a   Birkett, Donald J ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CYP1A2; CYP2C9; Cytochrome P450; Drug metabolism; Human liver; Naproxen

Indexed keywords

COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; MEPHENYTOIN; NAPROXEN; O DEMETHYLASE; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CELL LYSATE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; METHYLATION; MICROSOMES, LIVER; NAPROXEN; OXIDOREDUCTASES, O-DEMETHYLATING; RECOMBINANT PROTEINS; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0029916692     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)85085-4     Document Type: Article

References (24)

1. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K and Nebert DW, The P450 superfamily: Update of new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12: 1-51, 1993.
2. Gonzalez FJ, Human cytochromes P450: Problems and perspectives. Trends Pharmacol Sci 13: 346-352, 1992.
3. Gonzalez FJ, Molecular genetics of the P450 superfamily. Pharmacol Ther 45: 1-38, 1990.
4. Birkett DJ, Mackenzie PI, Veronese ME and Miners JO, In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14: 291-294, 1993.
5. Miners JO, Veronese ME and Birkett DJ, In vitro approaches for the prediction of human drug metabolism. Ann Reports Med Chem 29: 307-316, 1994.
6. Goldstein JA and de Morais SMF, Biochemistry and molecular biology of human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
7. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO and Birkett DJ, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175: 1112-1118, 1991.
8. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN and McManus ME, Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31: 125-130, 1991.
9. Miners JO, Rees DLP, Valente L, Veronese ME and Birkett DJ, Human hepatic cytochrome P450 catalyzes the rate limiting pathway of torasemide metabolism. J Pharmocol Exp Ther 272: 1076-1081, 1995.
10. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Reddy A, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF, Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: A role for P4502C9 in the etiology of S-warfarin drug interactions. Chem Res Toxicol 5: 54-59, 1992.
11. Tracy TS, Rosenbluth BW, Wrighton SD, Gonzalez FJ and Korzekwa KR, Cytochrome P4502C9 and an allelic variant catalyze the 4′-hydroxylation of R- and S-flurbiprofen. Biochem Pharmacol 49: 1269-1276, 1995.
12. TB (CYP2C): the major elimination pathway of (±) ibuprofen. Clin Pharmacol Ther 55: 208, 1994.
13. Newlands AJ, Smith DA, Jones BC and Hawksworth GM, Metabolism of non-steroidal anti-inflammatory drugs by cytochrome P450 2C. Br J Clin Pharmacol 34: 152P, 1992.
14. Antilla M, Haataja M and Kasanen A, Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 18: 263-268, 1980.
15. Runkel R, Chaplin MD, Sevelius H, Ortega E and Segre E, Pharmacokinetics of naproxen overdose. Clin Pharmacol Ther 20: 269-277, 1976.
16. McKinnon RA, Hall PD, Quattrochi LC, Tukey RH and McManus ME, Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and hepatocellular carcinoma by in situ hybridization. Hepatology 14: 848-856, 1991.
17. Lowry OH, Rosebrough NJ, Farr AL and Randall AJ, Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
18. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265: 401-407, 1993.
19. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations. Biochem Pharmacol 37: 1137-1144, 1988.
20. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH and Miners JO, Direct characterisation of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4: 281-284, 1994.
21. Wrighton SA, Stevens JC, Becker GW and Vanden Branden M, Isolation and characterisation of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306: 240-245, 1993.
22. Evans AM, Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 42: 237-256, 1992.
23. TB (CYP2C): A major monoxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 29-34, 1992.
24. Zhao J, Leemann T and Dayer P, In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 51: 575-581, 1991.